Greger R
Institut für Physiologie, Universität Freiburg, Fed. Rep. of Germany.
Arzneimittelforschung. 1988 Jan;38(1A):151-2.
The new diuretic torasemide (1-isopropyl-3- ([4-(3-methyl-phenylamino)pyridine]-3-sulfonyl)urea) was tested in isolated in vitro perfused cortical thick ascending limbs of Henle loops of rabbit kidney. The equivalent short circuit current (Isc) corresponding in this nephron segment to the rate of secondarily active Cl-reabsorption was measured continuously. Torasemide led to a rapid and reversible inhibition of Isc when added to the luminal perfusate. The IC50 for this effect was 3 x 10(-7) mol/l. A similar effect was also exerted by torasemide addition to the peritubular bath. However, 100 times larger doses were needed. The data are compatible with the view that torasemide interacts with both, the Na+2Cl-K+ carrier, localized in the luminal membrane, and, at higher concentrations, with the chloride channels present in the basolateral membrane of this nephron segment. Under normal conditions, and in the intact kidney, the former effect, i.e. interference with the Na+2Cl-K+ carrier will be the dominant action of this drug.
新型利尿剂托拉塞米(1-异丙基-3-([4-(3-甲基苯氨基)吡啶]-3-磺酰基)脲)在兔肾髓袢升支粗段离体灌注的皮质段进行了体外试验。连续测量该肾单位节段中与继发性主动氯离子重吸收速率相对应的等效短路电流(Isc)。当将托拉塞米添加到管腔灌注液中时,可导致Isc迅速且可逆地受到抑制。此效应的半数抑制浓度(IC50)为3×10⁻⁷mol/L。向肾小管周浴中添加托拉塞米也产生类似效应。然而,所需剂量要大100倍。这些数据支持这样的观点,即托拉塞米与位于管腔膜中的Na⁺2Cl⁻K⁺载体相互作用,并且在较高浓度时,与该肾单位节段基底外侧膜中存在的氯离子通道相互作用。在正常条件下以及在完整肾脏中,前者的效应,即干扰Na⁺2Cl⁻K⁺载体将是该药物的主要作用。